Suggested remit - to appraise the clinical and cost effectiveness of nivolumab within its marketing authorisation for treating small-cell lung cancer after platinum-based chemotherapy
Status In progress
Process STA 2018
ID number 1126

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
24 September 2018 - 22 October 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
05 December 2016 Referral

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance